Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850479 | 0.83 | HDAC3 (0.39) | CA2CYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL5557274 | 0.81 | CA2 (0.51) | CA2PTGS2SLC2A1CYP1A2CYP3A4 | |
| SCHEMBL4850745 | 0.80 | CYP2A6 (0.47) | CA2PTGS2 | |
| SCHEMBL30416457 | 0.79 | CA2 (0.50) | CA2BACE1PDE3BPDE3ACYP1A2 | |
| SCHEMBL4445648 | 0.78 | CA2 (0.49) | CA2BACE1PDE3BPDE3ACYP1A2 | |
| SCHEMBL5553012 | 0.77 | CA2 (0.48) | CA2PTGS2BACE1PDE3BPDE3A | |
| SCHEMBL5553145 | 0.77 | CA2 (0.48) | CA2BACE1PDE3BPDE3ACYP1A2 | |
| SCHEMBL5243924 | 0.75 | CA2 (0.51) | CA2BACE1PDE3BPDE3ACYP1A2 | |
| SCHEMBL4415170 | 0.74 | AKR1C2 (0.56) | CA2CYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL29239834 | 0.74 | CA2 (0.57) | CA2BACE1PDE3BPDE3ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117667-B1 | BENZOTHIENO[3,2-c]PYRIDINES AS ALPHA2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-6774129-B2 | ALPHA 2-ADRENOCEPTOR ANTAGONISTS; ANTIDEPRESSANTS AND TREATING PARKINSON'S DISEASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-10 | — | — | US | disclosed |
| EP-1119570-B1 | TRICYCLIC DELTA3-PIPERIDINES AS PHARMACEUTICALS | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1140934-B1 | BENZISOXAZOLES AND PHENONES AS ALPHA-2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-08 | — | — | EP | disclosed |
| US-6576640-B1 | Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-10 | — | — | US | disclosed |
| US-20020169178-A1 | Benzothieno[3,2-c]pyridines as alpha2 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-14 | — | — | US | disclosed |
| US-6426350-B1 | ALPHA-2 ADRENOCEPTOR ANTAGONISTS; USE TREATING NERVOUS SYSTEM DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-30 | — | — | US | disclosed |
| US-6352999-B1 | DRUGS FOR NERVOUS SYSTEM DISORDERS, PARKINSON'S DISEASE AND ANTIDEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-05 | — | — | US | disclosed |
| EP-1140934-A1 | BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| EP-1119570-A1 | TRICYCLIC DELTA3-PIPERIDINES AS PHARMACEUTICALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1117667-A1 | BENZOTHIENO[3,2-c]PYRIDINES AS ALPHA2 ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000037466-A1 | BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000020423-A1 | TRICYCLIC Δ3-PIPERIDINES AS PHARMACEUTICALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020422-A1 | BENZOTHIENO[3,2-c]PYRIDINES AS α2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169178-A1 | Benzothieno[3,2-c]pyridines as alpha2 antagonists | ADRB2, ADRB1, ADRA1D | CA2 562/4885PTGS2 359/4885BACE1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.